<SUBMISSION>
<ACCESSION-NUMBER>0001104659-03-020026
<TYPE>8-K
<PUBLIC-DOCUMENT-COUNT>4
<PERIOD>20030904
<ITEMS>5
<ITEMS>7
<FILING-DATE>20030904
<FILER>
<COMPANY-DATA>
<CONFORMED-NAME>CERUS CORP
<CIK>0001020214
<ASSIGNED-SIC>2836
<IRS-NUMBER>680262011
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>8-K
<ACT>34
<FILE-NUMBER>000-21937
<FILM-NUMBER>03881532
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>2411 STANWELL DR
<CITY>CONCORD
<STATE>CA
<ZIP>94520
<PHONE>9252886000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>2525 STANWELL DRIVE
<STREET2>STE 300
<CITY>CONCORD
<STATE>CA
<ZIP>94520
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>CERUS TECHNOLOGIES INC
<DATE-CHANGED>19960731
</FORMER-COMPANY>
</FILER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a03-3176_18k.htm
<DESCRIPTION>8-K
<TEXT>
<html>

<head>



</head>

<body>

<div style="font-family:'Times New Roman';">

<div style="border:none;border-top:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE
COMMISSION</font></b></p>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM 8-K</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT
REPORT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant
to Section&nbsp;13 or 15(d) of the<br>
Securities Exchange Act of 1934</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event
reported):<b><font style="font-weight:bold;">&#160;
September&nbsp;4, 2003</font></b></font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">CERUS CORPORATION</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact name of registrant as specified in
  its charter)</font></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.98%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.66%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">0-21937</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.72%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">68-0262011</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.98%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State of jurisdiction)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.66%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File No.)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.72%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer Identification No.)</font></p>
  </td>
 </tr>
 <tr>
  <td width="31%" valign="top" style="padding:0in 0in 0in 0in;width:31.98%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.66%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.64%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="30%" valign="top" style="padding:0in 0in 0in 0in;width:30.72%;">
  <p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">2411 Stanwell Drive<br>
  Concord, California 94520</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="100%" colspan="5" valign="top" style="padding:0in 0in 0in 0in;width:100.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices and
  zip code)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Registrant&#146;s telephone number, including area
code: <b><font style="font-weight:bold;">(925) 288-6000</font></b></font></p>

<div style="border:none;border-bottom:double windowtext 9.0pt;padding:0in 0in 0in 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\cmcclellan\03-3176-1\task23793\3176-1-be.htm',USER='cmcclel',CD='Sep  4 11:12 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.&#160; Other Events.</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On September&nbsp;4, 2003, Cerus Corporation (the &#147;Company&#148;) and
subsidiaries of Baxter International Inc. announced they are voluntarily
halting Phase III trials for their pathogen-inactivated red blood cell
program.&#160; A copy of the Company&#146;s press
release is attached as Exhibit 99.1 hereto and is incorporated herein by
reference.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 7.</font></b><b><font size="1" style="font-size:3.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font>Exhibits.</b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="9%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:9.4%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>
  Number</font></b></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.9%;">
  <p align="center" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:88.7%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description of Exhibit</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="9%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:9.4%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.9%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="88%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:88.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release, dated September&nbsp;4, 2003, entitled &#147;Baxter and
  Cerus halt red blood cell clinical trials for investigational pathogen
  inactivation system.&#148;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='2',FILE='C:\jms\cmcclellan\03-3176-1\task23793\3176-1-be.htm',USER='cmcclel',CD='Sep  4 11:12 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURE</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.6%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="52%" colspan="3" valign="top" style="padding:0in 0in 0in 0in;width:52.24%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">CERUS CORPORATION</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.6%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.56%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.68%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.6%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.14%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.56%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.68%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="47%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:47.76%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Dated:&#160;&#160; September&nbsp;4,
  2003</font></p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.56%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="34%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:34.44%;">
  <p style="margin:0in 0in .0001pt .1in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Gregory W. Schafer</font></p>
  </td>
  <td width="14%" valign="top" style="padding:0in 0in 0in 0in;width:14.24%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.6%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.56%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gregory W. Schafer</font></p>
  </td>
 </tr>
 <tr>
  <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.6%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.56%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice President, Finance and</font></p>
  </td>
 </tr>
 <tr>
  <td width="35%" valign="top" style="padding:0in 0in 0in 0in;width:35.6%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="12%" valign="top" style="padding:0in 0in 0in 0in;width:12.14%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="3%" valign="top" style="padding:0in 0in 0in 0in;width:3.56%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:48.68%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='3',FILE='C:\jms\cmcclellan\03-3176-1\task23793\3176-1-be.htm',USER='cmcclel',CD='Sep  4 11:12 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Index to Exhibits</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="9%" valign="top" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:9.4%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit<br>
  Number</font></b></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.9%;">
  <p align="center" style="font-size:1.0pt;margin:0in 0in .0001pt;text-align:center;">&nbsp;</p>
  </td>
  <td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext .5pt;padding:0in 0in 0in 0in;width:88.7%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description of Exhibit</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="9%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:9.4%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="1%" valign="bottom" style="padding:0in 0in 0in 0in;width:1.9%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="88%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:88.7%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release, dated September&nbsp;4, 2003, entitled &#147;Baxter and
  Cerus halt red blood cell clinical trials for investigational pathogen
  inactivation system.&#148;</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>


<!-- SEQ.=1,FOLIO='4',FILE='C:\jms\cmcclellan\03-3176-1\task23793\3176-1-be.htm',USER='cmcclel',CD='Sep  4 11:12 2003' -->
</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>a03-3176_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>

<head>



</head>

<body>

<div style="font-family:'Times New Roman';">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr height="41" style="height:30.6pt;">
  <td width="367" height="41" valign="top" style="height:30.6pt;padding:0in 5.4pt 0in 5.4pt;width:275.4pt;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="161" height="35" src="g31761kmimage002.gif"></font></p>
  </td>
  <td width="367" height="41" valign="top" style="height:30.6pt;padding:0in 5.4pt 0in 5.4pt;width:275.4pt;">
  <p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman"><img width="143" height="36" src="g31761kmimage004.gif"></font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.22%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Cerus</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">For Baxter</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.22%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.22%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Media:</font></i></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Media:</font></i></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.22%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Lorie Fiber, (323) 202-1046</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Tanya Tyska, (847) 270-4918</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.22%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Joe Streng, (916) 442-2331</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Deborah Spak, (847) 948-2349</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.22%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
  <p style="font-size:10.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.22%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Investor
  Relations:</font></i></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
  <p style="margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Investor
  Relations:</font></i></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.22%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Sylvia Wheeler, (925) 288-6061</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Neville Jeharajah, (847) 948-2875</font></p>
  </td>
 </tr>
 <tr>
  <td width="49%" valign="top" style="padding:0in 0in 0in 0in;width:49.22%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.7%;">
  <p style="font-size:1.0pt;margin:0in 0in .0001pt;">&nbsp;</p>
  </td>
  <td width="48%" valign="top" style="padding:0in 0in 0in 0in;width:48.08%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Mary Kay Ladone, (847) 948-3371</font></p>
  </td>
 </tr>
</table>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BAXTER AND CERUS HALT RED BLOOD CELL CLINICAL
TRIALS FOR<br>
INVESTIGATIONAL PATHOGEN INACTIVATION SYSTEM</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">CONCORD,
Calif. and DEERFIELD, Ill., September&nbsp;4, 2003&#151;Cerus Corporation (NASDAQ:
CERS) and subsidiaries of Baxter International Inc. (NYSE: BAX) today announced
they are voluntarily halting Phase III trials for their pathogen-inactivated
red blood cell program.&#160; The companies
made this decision as a precautionary measure after two study patients
developed antibodies to red blood cells treated with S-303, the compound used
in the companies&#146; investigational pathogen inactivation system for red blood
cells.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The two
patients who were enrolled in the Phase III trial showed an antibody response
but no clinical adverse events after transfusion with the S-303 treated red
blood cells. The antibody response was discovered using a standard blood test
that was employed as part of the clinical protocol. Antibodies are known to
arise in transfused patients and may not be physiologically active.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
observations from this trial do not affect the development or commercialization
of the pathogen inactivation programs for platelets and plasma, which use a
different technology and mechanism of action. The red blood cell technology
employs a compound called S-303, which is activated by the pH of blood. The
platelet and plasma technology uses a compound called S-59 (or </font>amotosalen),
which is activated by light. There is extensive, published data on the
safety profile of the platelet and plasma technology, including the amotosalen
compound, documenting no associated antibody response.</p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">- more -</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>


<div style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

<font size="2" face="Times New Roman" style="font-size:10.0pt;">
<!-- SEQ.=1,FOLIO='',FILE='C:\jms\cmcclellan\03-3176-1\task23793\3176-1-km.htm',USER='cmcclel',CD='Sep  4 11:15 2003' -->
<br clear="all" style="page-break-before:always;">
</font>

<p align="center" style="font-size:10.0pt;margin:0in 0in .0001pt;text-align:center;text-autospace:none;">&nbsp;</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The companies plan to evaluate the available clinical data to determine
the appropriate course of action for their investigational pathogen
inactivation system for red blood cells.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABOUT CERUS</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus Corporation is building on its leading position in the
biopharmaceutical industry by developing medical systems and therapeutics to
provide safer and more effective options to patients. The company is developing
products based on its proprietary Helinx<sup>&#174;</sup> technology for controlling
biological replication. Cerus&#146; most advanced programs are focused on systems to
enhance the safety of the world&#146;s blood supply. The Concord, California-based
company also is pursuing therapeutic applications of Helinx technology to treat
and prevent serious diseases.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ABOUT BAXTER</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Baxter International Inc., through its subsidiaries, assists health-care
professionals and their patients with treatment of complex medical conditions,
including cancer, hemophilia, immune disorders, kidney disease and trauma.&#160; The company applies its expertise in medical
devices, pharmaceuticals and biotechnology to make a meaningful difference in
patients&#146; lives.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">###</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cerus has scheduled a conference call for 10 a.m. EDT today to discuss
this announcement.&#160; Interested parties
can access a live Internet broadcast at:</font>
http://www.firstcallevents.com/service/ajwz388455970gf12.html.&#160; For those unable to listen to the live
broadcast, the call will be archived at www.cerus.com.</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="font-size:10.0pt;margin:0in 0in .0001pt;"><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;">Helinx</font></i> is a
trademark of Cerus Corporation</p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Statements in this news release regarding clinical trials, regulatory
filings, product development, potential efficacy against emerging pathogens and
commercial potential are forward-looking statements that involve risks and
uncertainties. Actual results could differ materially from the above
forward-looking statements as a result of certain factors, including the risks
and uncertainty of the timing, rates of enrollment and results of clinical
trials and other development activities, actions by regulatory authorities at
any stage of the development process, additional financing activities,
manufacturing, market acceptance of any products, competitive conditions and
other factors discussed in the company&#146;s most recent filings with the
Securities and Exchange Commission.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>


<div style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">

<hr size="2" width="100%" noshade color="gray" align="left">

</font></div>

</div>


<!-- SEQ.=1,FOLIO='2',FILE='C:\jms\cmcclellan\03-3176-1\task23793\3176-1-km.htm',USER='cmcclel',CD='Sep  4 11:15 2003' -->
</body>

</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g31761kmimage002.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31761kmimage002.gif
M1TE&.#EAH0`C`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````H0`C`(8````S``!F``"9````,P`S,P!F,P"9,P```#,S`#-F`#.9`#,`
M,S,S,S-F,S.9,S/,,S,S9C-F9C.99C,S,V9F,V:9,V;,,V8S9F9F9F:99F;,
M9F9FF6:9F6;,F6:99IEFF9F9F9G,F9G_F9F9S)G,S)G_S)EF9IF9F<S,F<S_
MF<R9S,S,S,S_S,S,_\S__\S,S/__S/_,______\!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,&_\"9<$B<:2;%I'+)
M;#J?T*AT2I6*`@)1=<OM>K]@YDLA&`1BX;1ZS>8N!`Z!P*!FL5IW.\S.>CUE
M?2Q[?'8M1(""+"Y[+H2#,DZ$@DZ-A)!+,!T=(1\?'2`=GB"<(!PE3`]R`P)D
M!UX="0"RL[2S%4LM#;6[LT0?O,"S$DHOM01.NK1:12+!P0E+&G(*<7("&EL=
MSKNW1<7;M40AX,`=13*UT$W)LRA%Y+P,2B-P!]9Q!@*G4^SP&<SP:(D+N`O$
MNW!-*-1:)@0!05H%E%@C,Z":`3+\'@+H)B2%1@`#/\HZ.$L=$P>U5@SY)=+D
MD(KV%.0K0T;!``51QCESN.O?$/^1(45B&!*C5@!D"W^*!!"12"HY]EA=S#?S
M`11@!J/TF\7`4,Y:$8;(>(%&1HBM`(XIY>HD0JT4:VGYI/*!%2N9`A9<O'GS
MH@4G&G8AH,++!16=LX8R@;&+B%&DM$@(8;$KQ!86`NQ%E3,3CC4Y*IH4V.5'
MBK9:<Z4@EN7`2>.X3)U@J.5N!DN!6R[:U:V@YLRI,IOL<@EE-,+#M88)/SZC
MUN!U*86<GO6<R@9K]M[D.X`7#D4R'Y90KF5YRBYY5:;+HN":N7,G*&F5ORU+
M+14Y<7KG>T.&U9M5W2W!P6OFU9(5%2#4PI$2Z+A'RU%-S*;,9+N<0(4)9&@W
M#6=E4(7_5T7Z*%$!@5%\0PL##:2HXHH-1)!B6$.L!H!R2I2PBWW-G0C9+/OD
M6$L!&00I9`82C'+)$-+,81->!MSDF5U.DO%7$EM5%P4)2X$4(SD!`!,>;!`R
MX=:$0@@UQ`,&O,&935(YZ<`J!N!3D1*QT$+<$S8NY4N6),G2%!-;E3>#"WK.
MX*9N2N;377YYZ:;$>51X5*@0,A+48YDZ-C'F+`S-<(*>_:V2UV=S2(7?1'0D
M4><L?T:1)U!;?L1"$N\E%!T1)'2I40A-X@/'5`OD!^!^N@V@Q*:RA!E%,^DT
M@&**!:"8@(H,3!M40(+V"<"=12`+0*=#L.!`G0$@$``!VP+#_T!-HZH2:CYO
M6L.;$FA1P5@MDE5!'U,82%`!!15DL(MA210%T8ZR7"H%H;M0A1^(4K$+!\3Y
M**'>2(2AMH6,J0E1Y1*UH`<H;5Q(2LL;;T1U451];<C*3:XD,1YN!1Y<A8PT
M.F;@H\PI@2XMI571("T0E-K;`$Z::E,<;^*U`,@:9]3S5[0L.(1"4_O8RW(T
M5S'S+"&4NJ9G%LD$9W\;+&%<UU"8G-C-M2A&:]1$_#R+2KB02(6$LQQS5Y-L
M;EB-76SB)!XO5-@]"XRJ@;7$B%,SH'?=DT<A\(\SH`G@'`Z0`3A^39;Z-!.Z
M&I4B!@U0$`$&$3C@(D.5RI*`Z[13T/]`!:TO>+'5.M/"WK5@%]$"3[3D/+.N
MI8/S3PL!3*6*DIQ'>5$"7C'Q4<YK$T1$@E4SL:^6O?-R;C!%K,"G$!;@)U.&
M$UDC*A).F!A0SEH'M"<MC/-,2P-%O$H0-D3PWT/X-X1\K&(5^%!`3"["-"D\
MA'=HV081+B8W)50*#?<+"`&)X#:";%`(,2`#TZRAEPZ500!!@T('DN<,^DTF
M>Q*,E2W:\Z`DW(L<X!(""C02@-HD`5&F>A)&N/`!##"@``DX8K48P(!SF8,)
M)*B`LZ)%`"06`(D`$-D,5I``)"(``1U+0@D0<,0D`J!ZAZA``10'``0D(`(P
M$,/M&H"!VMTHKG5U=,`'LK6$ZSBO/W.X0!L&2<A"AB$$3QF``1[@`4,Z\I&0
&'$(0```[
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g31761kmimage004.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g31761kmimage004.gif
M1TE&.#EACP`D`'<`,2'^&E-O9G1W87)E.B!-:6-R;W-O9G0@3V9F:6-E`"P`
M````CP`D`(4``#,``&8``)D`,S,`,V8`,YDS`#,S`&8S,S,S,V8S,YDS9F8S
M9IDS9LQF,V9F,YEF9F9F9IEF9LQFF9EFF<R99IF99LR9F9F9F<R9S)F9S,R9
MS/_,F9G,F<S,F?_,S)G,S,S,S/_,_\S,____S,S_S/___\S___\!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!
M`@,!`@,!`@,!`@,!`@,!`@,!`@,&_\"3<*@)#`((XR%Y(""2`P.!8"1HAMBL
M=LOM>K6EKWA,_FH&S68`0!@<`P$J^W`X#CKEO%X[XIKV@'L@`&L$``D$!P$'
M`&B+5`-4B@.!E61_)R9AEIQC%TIQ`09'5(:1HHM5`""=K5\E(WVNLR<1:&T&
MH5%KA&Q538T1M*X=%!01#(@#%<.=?PEP<&V+"0T,#,B*B6]P#X&P8K)Y&(WE
M<`!79.+-6G5.A,`7646Y!%))PD+KF5S[0I@G1@#TLFZ3+6U-VH3`,K`+0'_Z
MAO1I*'&+"#BW$%`)P"K+*2EK`F"@^*V2"5D/#-D[DHN?EC^;Q&@"X^<+""?2
MUDCYMRG$*/\U309`;$:2BZ%0D!*PZR2!4!(H<;1\`A:II9`+%RA@U6J!`H:O
M%S!DQ4!!2X@)6LE>Z'HAW18-%K!:F'#B8R)&!2Y$T%LAP@>78L=JW<KVP@0\
M6;QF73L!PU6Q7K5F4?#FB!JE`8<P&$`H42DA)-@`Z!72CA%4HQUCJ1.R4<B8
M6$*,3@(`0PF,<1K):1T@7XB-J!P9&5TJ3D<AA'A3,H4Z0)8$4+2-SO?O1())
MB@`@8'`5#K`V"7*=.HH3`2M9GQ`A0:KZN73'%(Q(T6:`]=-5)TIPKA)M3M#L
M":`ASG<#A*<`!-)TMAT6(^"FD1+M\4-*%50P<\("[L`3C3V'E*+_"!R8#1&-
M%-JMH4!^U2V0&P`2"&%+$J>=-J$1?3"@1"+:33-A)&\`<&(F^WT8AP$YQL&(
M!5B`$`DCAD`A0A:RX82:+%(D@LB5"<$QWQ$P/CD$!)P!M]YQ)R!(8HN9`)=$
M`H@L(0H":""'`#!Q")!*$S#2820!0A015!O:G(/&$5YV%T<BYP2P00<:=`!"
M"`LDYTZ!^EP0@@DBQ!(""2,\N=`"D,3!980A/.(.;64)8>-IWJ!8AT;)!9``
M"!IL\"BM)X"0TS:RAJ`!"!TPH%L41^!W@2_!K:%1J,YA$<$[DU`QBB^&2#&*
ME'25@0&1:?32WA\Z+B(:G[4,"0!W6'"#_\01\FQ!CK0J!>"6$.LA=0`K#ZR!
M$!*JA5&""`Y,5D]5_/D"4BCGH+N%0!$),0$;;VPS[PG'IK'D$2"0\\:/LNC*
MVD8`;,"%L+^(YJ\0)22'J"%70#(-%2%Z44@J1DH3+1OW#.#!'OG2@<L1)%1'
M+WG>R6J9K%F88$&83ZW1!32>#=DL$5NR%$`?=W(X``3\B`-3'R.0`A*,:(BV
M"&O)A?A'!@E-H08!;,Y\M"A;("BU&Z?]M`5E-%.!0!?UE@UW%A'D)*IS^N%-
M;81<=."=:5.P<5?DH29Q'#E%B^T+ET:Z,7AF0UR$T]$/#G!I.^M='+-'1B0@
M.0#4"1%ITXH<</^"XXHDP>%0`?TQ011N1YV)""&,H$$:<(?R8UU-VT,>(W4X
M5?3J0PBYS48'#(4WDX3$'MLM<"#060(*+*!`W$=%PD8MI-`)P!C7R5$/``$/
M`6ZQI34;06>G6`9Y^*=)1*JD(A]F#8!Q$@'`G];3+@)6RT.5R5^>8'>"S81*
M#6/PT#2,@*:(7`]YMCL!3A0Q'S;$#V[40D)J4*2%L2W"$9B!S>T(89FCD`D+
M=FN?V#[H&7<$(`/6$<7**"4&%8;B"0%`#!9P)J/U-4@5I^$:%A1@I'K`H5!:
M6%6"I,6%A\%(#N2RWQ`4\`1$X:\SXN%%:UBQ']/TQ@M_:)#?<A&-)\7_1#8(
MN\P).*!#:2T$"[P"5!M>L@DE:>1![LA6%J)61D7P@5[)P=M\X-:$ZZ0!`04(
MT`E*=0K=`6"`7<#<H=B@$0:=``-<<IXH3F0C>WB'"EK886[":$H11N.%T;!=
M"0;BL@U13Q^DE`05N-.'2PDD%@&!Q4(X\,K._=$+$H@#$TX30AS2S#1TP4D;
M3A&B,."1":+Q'B"'53F,::&*@`*`(K.@JQ[)P3%%(9SGZC4U+ZBH%U.`@\*&
M`(W^Q:,NV$/%B0""@0`":@"@Q`(#TJ"E'G:#G?P)%`*%0`%AP@@`"Y%ATH2@
M`!)*(Q(9Y-P!I#"`#HK($:Q1Q$)>")(V>"\"_[HCTCF>J=!S.(\4$$M"%CI0
M+/4EH5#KB`!)PY>(+,@"(BUU0RY^>4[=M4$25X"%)B:0A%',\GUUT44N#&#2
M$U"1FH!RR1#V1Z($""MWUP3E!7*!O#7LC"(JPJ6HQ#H03)SD!*U+A4O%T`'7
M0(]:3HA:<09U`,S8+(#[%*%&$I([%H;A81XJP08BH1(IQ:P(#TIC`[/P@,T9
MD7?L3*/;`+!9+E3`C,5A`KQVH;MHH"L\[=..`B71HR:V:@@5*(1V9*$`27GV
M/']`2B1TQXJ3E"`$\L"`WQXA"@:`X+G/M96O'M4!NGP"4>)3J1A(MEC.D6>(
MZWE0MB@PKAB]3)#SB>$#,S"AW*I@=`B_0\11K!J[Q2KPEG."FWY/<!&H=88\
MG%OL<,HB+&8-4@P^TU(`1:,[ALI!.U@`18,)(=.W`=`M-XG5O$:0'0LC`0N0
M'1>LA'DNV2%E/0Y],$[!A58<U9,+@\#9RW*GAC#1L&:(Z<,&7C?+W%34?[E1
MC09H6`?'A$$6RAC2`*``2@7T<",JP5DZ1N"ZV0XG?7MZ&W(B=U6Q;J$`4@N%
M#PUAL3VQ`8$><)TCGE+8(%*V'EPK58(F>M;BK*>:0D!0F'[BF5P$;0@40,1L
0/_8=&<GC`ME9LQ'$$`0`.S\_
`
end

</TEXT>
</DOCUMENT>
</SUBMISSION>
